Welcure Drugs [WELCURE] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Welcure Drugs
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Welcure Drugs wins in 11 metrics, Aarti Drugs wins in 8 metrics, with 0 ties. Welcure Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Welcure Drugs | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 4.43 | 22.81 | Welcure Drugs |
| Price-to-Book Ratio | 0.89 | 3.14 | Welcure Drugs |
| Debt-to-Equity Ratio | 120.18 | 44.92 | Aarti Drugs |
| PEG Ratio | 0.00 | 0.36 | Welcure Drugs |
| EV/EBITDA | 7.51 | 16.76 | Welcure Drugs |
| Profit Margin (TTM) | 7.96% | 7.80% | Welcure Drugs |
| Operating Margin (TTM) | 10.38% | 10.11% | Welcure Drugs |
| EBITDA Margin (TTM) | 10.38% | 10.11% | Welcure Drugs |
| Return on Equity | 2.12% | 12.28% | Aarti Drugs |
| Return on Assets (TTM) | 0.81% | 6.53% | Aarti Drugs |
| Free Cash Flow (TTM) | $-2.22B | $674.20M | Aarti Drugs |
| Dividend Yield | N/A | 0.22% | N/A |
| 1-Year Return | 62.62% | -14.34% | Welcure Drugs |
| Price-to-Sales Ratio (TTM) | 0.41 | 1.77 | Welcure Drugs |
| Enterprise Value | $2.57B | $49.56B | Aarti Drugs |
| EV/Revenue Ratio | 0.79 | 2.05 | Welcure Drugs |
| Gross Profit Margin (TTM) | 10.40% | 36.77% | Aarti Drugs |
| Revenue per Share (TTM) | $38 | $265 | Aarti Drugs |
| Earnings per Share (Diluted) | $2.69 | $20.65 | Aarti Drugs |
| Beta (Stock Volatility) | -1.76 | 0.21 | Welcure Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Welcure Drugs vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Welcure Drugs | -4.94% | 0.68% | 19.32% | 11.19% | 72.25% | 7.48% |
| Aarti Drugs | 2.56% | -4.13% | -10.00% | 1.76% | 27.10% | 6.05% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Welcure Drugs | 62.62% | 50.13% | 496.00% | 354.96% | 254.76% | -12.09% |
| Aarti Drugs | -14.34% | 10.27% | -34.08% | 237.25% | 2,680.94% | 2,426.41% |
Performance & Financial Health Analysis: Welcure Drugs vs Aarti Drugs
| Metric | WELCURE | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.34B | ₹42.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 7,522,990 | 149,023 |
| 90 Day Avg. Volume | 3,381,856 | 593,839 |
| Last Close | ₹11.92 | ₹483.05 |
| 52 Week Range | ₹6.40 - ₹15.89 | ₹312.00 - ₹635.00 |
| % from 52W High | -24.98% | -23.93% |
| All-Time High | ₹25.00 (Sep 19, 2005) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -52.32% | -52.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -34.93% | 0.06% |
| Quarterly Earnings Growth | N/A | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.08% | 0.08% |
| Operating Margin (TTM) | 0.10% | 0.10% |
| Return on Equity (TTM) | 0.02% | 0.12% |
| Debt to Equity (MRQ) | 120.18 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹13.32 | ₹149.84 |
| Cash per Share (MRQ) | ₹0.01 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹-2,249,340,000 | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹21.70M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.22% |
| Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Welcure Drugs vs Aarti Drugs
| Metric | WELCURE | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 4.43 | 22.81 |
| Forward P/E | N/A | 14.86 |
| PEG Ratio | 0.00 | 0.36 |
| Price to Sales (TTM) | 0.41 | 1.77 |
| Price to Book (MRQ) | 0.89 | 3.14 |
| Market Capitalization | ||
| Market Capitalization | ₹1.34B | ₹42.99B |
| Enterprise Value | ₹2.57B | ₹49.56B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.79 | 2.05 |
| Enterprise to EBITDA | 7.51 | 16.76 |
| Risk & Other Metrics | ||
| Beta | -1.76 | 0.21 |
| Book Value per Share (MRQ) | ₹13.32 | ₹149.84 |
Financial Statements Comparison: Welcure Drugs vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | WELCURE | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹3.00B | ₹6.77B |
| Cost of Goods Sold | ₹2.69B | ₹4.37B |
| Gross Profit | ₹311.96M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹311.36M | ₹784.50M |
| EBITDA | ₹311.41M | ₹951.90M |
| Pre-Tax Income | ₹311.36M | ₹711.50M |
| Income Tax | ₹78.37M | ₹83.80M |
| Net Income (Profit) | ₹232.99M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | WELCURE | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹1.28M | ₹45.80M |
| Total Current Assets | ₹1.82B | ₹13.38B |
| Total Current Liabilities | ₹412.69M | ₹8.37B |
| Long-Term Debt | ₹1.23B | ₹2.86B |
| Total Shareholders Equity | ₹1.03B | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | N/A | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | WELCURE | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | WELCURE | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 7,522,990 | 149,023 |
| Average Daily Volume (90 Day) | 3,381,856 | 593,839 |
| Shares Outstanding | 112.51M | 91.27M |
| Float Shares | 11.04M | 35.46M |
| % Held by Insiders | 0.88% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Welcure Drugs vs Aarti Drugs
| Metric | WELCURE | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.22% |
| 3-Year Avg Annual Dividend | N/A | ₹1.00 |
| 3-Year Avg Dividend Yield | N/A | 0.23% |
| 3-Year Total Dividends | N/A | ₹3.00 |
| Ex-Dividend Date | N/A | Feb 04, 2025 |